Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1952 1
1954 1
1956 2
1959 2
1960 1
1961 3
1962 1
1964 1
1965 1
1966 1
1967 2
1968 2
1969 6
1972 1
1973 1
1975 2
1976 2
1977 1
1979 1
1980 2
1981 3
1982 1
1983 3
1985 1
1986 1
1988 3
1989 5
1990 3
1991 4
1993 4
1994 1
1995 1
1996 2
1997 3
1998 1
1999 4
2002 2
2003 1
2005 1
2006 2
2007 3
2008 7
2009 3
2010 2
2011 2
2012 4
2013 5
2014 5
2015 7
2016 8
2017 8
2018 6
2019 11
2020 14
2021 16
2022 23
2023 27
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

214 results

Results by year

Filters applied: . Clear all
Page 1
Adult congenital heart disease: a review of the simple lesions.
Prica M, Kamalathasan S, Gopaul K, Warriner D. Prica M, et al. Br J Hosp Med (Lond). 2022 Jan 2;83(1):1-12. doi: 10.12968/hmed.2021.0302. Epub 2022 Jan 26. Br J Hosp Med (Lond). 2022. PMID: 35129382 Free article. Review.
Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines.
Thavendiranathan P, Houbois C, Marwick TH, Kei T, Saha S, Runeckles K, Huang F, Shalmon T, Thorpe KE, Pezo RC, Prica A, Maze D, Abdel-Qadir H, Connelly KA, Chan J, Billia F, Power C, Hanneman K, Wintersperger BJ, Brezden-Masley C, Amir E. Thavendiranathan P, et al. Eur Heart J Cardiovasc Pharmacother. 2023 Sep 20;9(6):515-525. doi: 10.1093/ehjcvp/pvad031. Eur Heart J Cardiovasc Pharmacother. 2023. PMID: 37120736 Clinical Trial.
Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma.
Vijenthira A, Kuruvilla J, Crump M, Jain M, Prica A. Vijenthira A, et al. J Clin Oncol. 2023 Mar 10;41(8):1577-1589. doi: 10.1200/JCO.22.00478. Epub 2022 Oct 31. J Clin Oncol. 2023. PMID: 36315922
A bacteraemia risk prediction model: development and validation in an emergency medicine population.
Julián-Jiménez A, González Del Castillo J, García-Lamberechts EJ, Huarte Sanz I, Navarro Bustos C, Rubio Díaz R, Guardiola Tey JM, Llopis-Roca F, Piñera Salmerón P, de Martín-Ortiz de Zarate M, Álvarez-Manzanares J, Gamazo-Del Rio JJ, Álvarez Alonso M, Mora Ordoñez B, Álvarez López O, Ortega Romero MDM, Sousa Reviriego MDM, Perales Pardo R, Villena García Del Real H, Marchena González MJ, Ferreras Amez JM, González Martínez F, Martín-Sánchez FJ, Beneyto Martín P, Candel González FJ, Díaz-Honrubia AJ; INFURG-SEMES investigators. Julián-Jiménez A, et al. Infection. 2022 Feb;50(1):203-221. doi: 10.1007/s15010-021-01686-7. Epub 2021 Sep 6. Infection. 2022. PMID: 34487306
Connecting the Dots.
Rush RP, Saltman AP, Prica AA, Breiner A, Detsky AS. Rush RP, et al. N Engl J Med. 2017 Sep 7;377(10):978-984. doi: 10.1056/NEJMcps1613804. N Engl J Med. 2017. PMID: 28877025 No abstract available.
214 results